Skip to main content
Terug
RXRX logo

Recursion Pharmaceuticals, Inc.

Datakwaliteit: 100%
RXRX
NASDAQ Healthcare Biotechnology
€ 3,23
▼ € 0,02 (-0,62%)
Marktkapitalisatie: 1,44B
Dagbereik
€ 3,22 € 3,33
52-Weeksbereik
€ 2,98 € 7,18
Volume
11.126.219
50D / 200D Gem.
€ 3,92 / € 4,80
Vorige Slotkoers
€ 3,25

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (626 peers)

Metriek Aandeel Sector Mediaan
P/E -2,2 0,4
P/B 1,3 2,9
ROE % -59,5 3,7
Net Margin % -863,4 3,9
Rev Growth 5Y % 65,3 10,0
D/E 0,1 0,2

Koersdoel Analisten

Hold
€ 11,00 +240.6%
Forward WPA
-€ 0,95
Omzet Sch.
85 M

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2029 -€ 0,94
-€ 2,00 – -€ 0,51
250 M 4
FY2028 -€ 0,45
-€ 0,95 – -€ 0,24
440 M 3
FY2027 -€ 0,85
-€ 0,99 – -€ 0,66
140 M 6

Belangrijkste Punten

Revenue grew 65,31% annually over 5 years — strong growth
Debt/Equity of 0,07 — conservative balance sheet
Negative free cash flow of -378,28M
PEG of 0,19 suggests growth is underpriced
Revenue growth is decelerating — 1Y growth trails 5Y average by 38,39%
Capital efficient — spends only 8,66% of revenue on capex

Groei

Revenue Growth (5Y)
65,31%
Revenue (1Y)26,92%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-59,54%
ROIC-40,21%
Net Margin-863,35%
Op. Margin-867,87%

Veiligheid

Debt / Equity
0,07
Current Ratio5,50
Interest Coverage-358,08

Waardering

P/E Ratio
-2,24
P/B Ratio1,28
EV/EBITDAN/A
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 26,92% Revenue Growth (3Y) 30,46%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 65,31% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 74,68M Net Income (TTM) -644,76M
ROE -59,54% ROA -43,74%
Gross Margin -61,96% Operating Margin -867,87%
Net Margin -863,35% Free Cash Flow (TTM) -378,28M
ROIC -40,21% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,07 Current Ratio 5,50
Interest Coverage -358,08 Dividend Yield 0,00%
Valuation
P/E Ratio -2,24 P/B Ratio 1,28
P/S Ratio 19,34 PEG Ratio 0,19
EV/EBITDA N/A Dividend Yield 0,00%
Market Cap 1,44B Enterprise Value 779,10M

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 74,68M 58,84M 43,88M 39,68M 10,00M
Net Income -644,76M -463,66M -328,07M -239,48M -186,48M
EPS (Diluted) -1,44 -1,69 -1,58 -1,36 -1,05
Gross Profit -46,27M 13,60M 1,29M -8,59M 10,00M
Operating Income -648,13M -479,00M -350,06M -245,73M -182,78M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 1,47B 1,45B 653,70M 701,29M 610,35M
Total Liabilities 343,27M 413,82M 190,26M 215,48M 67,41M
Shareholders' Equity 1,13B 1,03B 463,44M 485,81M 542,94M
Total Debt 77,97M 108,49M 50,67M 51,01M 11,48M
Cash & Equivalents 743,29M 594,35M 391,57M 549,91M 285,12M
Current Assets 812,85M 714,27M 438,14M 569,81M 534,72M
Current Liabilities 147,71M 187,47M 93,17M 100,27M 46,66M

Strategiescores

This stock passed the criteria for 1 strategy

Score = fit strength (0–100)
Rank = position among all matches
Custom Full Throttle
#99 of 146
34

Recente Activiteit

Ingestapt Full Throttle
Mar 24, 2026